INDIA GLYCOLS LIMITED & 2 Ors v TEXAN MINERALS AND CHEMICALS LLC

Case Details

• Citation: [2025] SGHC 28
• Court: General Division of the High Court of the Republic of Singapore
• Decision Date: 21 February 2025
• Coram: Kristy Tan JC
• Case Number: Originating Application No 963 of 2024
• Hearing Date(s): 6, 13 January 2025
• Claimants / Plaintiffs: India Glycols Ltd; IGL Chem International USA LLC; Dharmesh Mehta
• Respondent / Defendant: Texan Minerals and Chemicals LLC
• Counsel for Claimants: Siraj Omar SC, Larisa Cheng and Robbie Tan (Siraj Omar LLC)
• Counsel for Respondent: Colin Seow Fu Hong and Huang Qianwei (Colin Seow Chambers)
• Practice Areas: International arbitration; Setting aside of arbitral awards; Breach of natural justice; Excess of jurisdiction

Summary

The decision in India Glycols Ltd & 2 Ors v Texan Minerals and Chemicals LLC [2025] SGHC 28 serves as a critical reminder of the jurisdictional boundaries that constrain arbitral tribunals, particularly in multi-party disputes where the scope of the arbitration agreement may be broader than the underlying substantive contracts. The High Court was tasked with determining whether a portion of an arbitral award, which imposed joint and several liability on a parent company, its subsidiary, and a director, should be set aside under the International Arbitration Act 1994 (2020 Rev Ed) ("IAA") and the UNCITRAL Model Law on International Commercial Arbitration ("Model Law").

The dispute originated from the supply of hand sanitisers during the COVID-19 pandemic. The Tribunal had found that the respondents in the arbitration (the Claimants in this application) breached a Manufacturer Representation Agreement ("MRA") by failing to ensure that manufacturing facilities were compliant with the US Food and Drug Administration’s ("FDA") current Good Manufacturing Practices ("cGMP"). While the Tribunal awarded damages of US$261,275.89 against all three parties, the High Court found that only the parent company, India Glycols Ltd ("IGL"), was a party to the MRA. The subsidiary, IGL Chem International USA LLC ("ICI"), and the director, Dharmesh Mehta, were signatories to a later Arbitration Agreement but were not parties to the MRA itself.

The Court’s analysis focused on two primary grounds: breach of natural justice (Ground 1) and excess of jurisdiction (Ground 2). Under Ground 1, the Court rejected the Claimants' argument that the Tribunal had adopted a "chain of reasoning" regarding the counterfactual scenario (i.e., whether the products could have been sold if they were cGMP-compliant) that was not addressed by the parties. Applying the principles in [2022] 1 SLR 1080, the Court held that the Tribunal’s reasoning was a foreseeable outgrowth of the issues pleaded and did not constitute a procedural unfairness.

However, Ground 2 proved fatal to a portion of the award. The Court held that the Tribunal exceeded its jurisdiction by holding ICI and Dharmesh Mehta liable for damages arising from a breach of the MRA. Because the issue of their liability for MRA-based damages was never submitted to arbitration—and because they were not parties to the MRA—the Tribunal lacked the authority to impose such liability. Consequently, the Court ordered a partial setting aside of the award, exonerating ICI and Dharmesh Mehta from the damages award while maintaining the liability of IGL. This judgment reinforces the "minimal curial intervention" principle while simultaneously asserting the Court's role in policing the strict jurisdictional limits of an arbitrator's mandate.

Timeline of Events

1. September 2020 – March 2021: Texan Minerals and Chemicals LLC ("Texan") placed purchase orders with IGL Chem International USA LLC ("ICI") for hand sanitisers manufactured by India Glycols Ltd ("IGL").
2. 23 February 2021: Texan and IGL executed the Manufacturer Representation Agreement ("MRA"), appointing Texan as the exclusive distributor in North America.
3. May 2021: The date by which the Tribunal later determined the respondents should have achieved cGMP compliance for their manufacturing facilities.
4. 3 May 2022: Counsel for Texan wrote to IGL alleging breaches of the MRA and non-compliance with US FDA cGMP standards.
5. 1 March 2023: Texan, IGL, ICI, and Dharmesh Mehta executed a standalone Arbitration Agreement to resolve disputes related to the hand sanitiser sales.
6. 16 March 2023: Texan commenced arbitration proceedings against IGL, ICI, and Dharmesh Mehta.
7. 19 June 2024: The Tribunal issued the Final Award, finding all three respondents liable for breach of the MRA and awarding damages.
8. 6, 13 January 2025: Substantive hearing of the setting-aside application (OA 963/2024) before the High Court.
9. 21 February 2025: The High Court delivered judgment, partially setting aside the award.

What Were the Facts of This Case?

The factual matrix involves a complex international supply chain for chemical products. India Glycols Ltd ("IGL") is an Indian manufacturer of various chemicals. Its wholly-owned subsidiary, IGL Chem International USA LLC ("ICI"), based in Texas, handles the marketing and distribution of these chemicals in the United States. Dharmesh Mehta is a director and board member of ICI. The Respondent, Texan Minerals and Chemicals LLC ("Texan"), is a Houston-based company involved in the international wholesale and supply of industrial products.

During the height of the COVID-19 pandemic, between September 2020 and March 2021, Texan placed purchase orders with ICI for hand sanitisers. These products were manufactured by IGL in India and shipped directly to Texan. The initial transactions were governed by individual purchase orders. However, on 23 February 2021, the relationship was formalised through the Manufacturer Representation Agreement ("MRA"), signed only by IGL and Texan. Clause 4.8 of the MRA was central to the dispute, as it required IGL to maintain a quality assurance program, including "GMP as required by US FDA."

Following the execution of the MRA, Texan placed orders for hand sanitisers in retail containers. Upon receipt, Texan alleged significant quality issues and discovered that the manufacturing facilities in India did not meet the US FDA’s current Good Manufacturing Practices ("cGMP") standards. Texan subsequently refused to pay invoices totalling US$127,698.20 for the retail containers. In May 2022, Texan demanded that IGL take back the products and reimburse expenses amounting to US$1,050,000.

To resolve the escalating conflict, the parties—IGL, ICI, Dharmesh Mehta, and Texan—entered into a specific Arbitration Agreement on 1 March 2023. This agreement referred "any and all disputes, claims, differences or controversies arising out of and/or in connection with the sale of IGL’s hand sanitizer products to Texan" to arbitration under the Singapore International Arbitration Centre (SIAC) rules. Texan subsequently filed its Notice of Arbitration on 16 March 2023.

In the arbitration, Texan sought various reliefs, including damages for breach of the MRA, breach of implied warranties under the Sale of Goods Act 1979, and misrepresentation. The Tribunal ultimately dismissed the claims based on misrepresentation and the Sale of Goods Act 1979. However, it found that IGL had breached the MRA by failing to bring its facilities up to cGMP compliance within a reasonable period (by May 2021). Crucially, the Tribunal held that all three respondents (IGL, ICI, and Dharmesh Mehta) were liable for this breach and ordered them to pay damages of US$261,275.89. This figure was derived from Texan’s storage and disposal costs of US$388,974.09, minus the set-off of US$127,698.20 for the unpaid invoices.

The Claimants (IGL, ICI, and Dharmesh) challenged this award in the High Court, arguing that the Tribunal had no basis to hold ICI and Dharmesh liable for a contract (the MRA) they never signed, and that the Tribunal had breached natural justice by making findings on a counterfactual scenario that was not properly ventilated during the hearing.

What Were the Key Legal Issues?

The High Court identified two primary legal issues, each corresponding to a statutory ground for setting aside an arbitral award:

• Issue 1: Breach of Natural Justice (Ground 1) – Whether the Tribunal breached the fair hearing rule under s 24(b) of the IAA and Art 34(2)(a)(ii) of the Model Law. The Claimants argued that the Tribunal’s finding—that Texan would have been able to sell the products if they were cGMP-compliant—was a "new" chain of reasoning that they were not given an opportunity to address. This issue required the Court to determine if the Tribunal’s logic was a "reasonable outgrowth" of the parties' cases.
• Issue 2: Excess of Jurisdiction (Ground 2) – Whether the Tribunal exceeded its jurisdiction under Art 34(2)(a)(iii) of the Model Law by awarding damages against ICI and Dharmesh Mehta for breach of the MRA. This issue turned on whether the question of ICI’s and Dharmesh’s liability for MRA-based damages had been "submitted to arbitration" and whether the Tribunal’s decision fell within the scope of that submission.

How Did the Court Analyse the Issues?

The Court’s analysis was exhaustive, spanning 57 pages and meticulously reviewing the arbitral record, including the pleadings, transcripts, and the Award itself.

Analysis of Ground 1: Breach of Natural Justice

The Claimants contended that the Tribunal’s decision on damages was based on a premise that was never argued: that in the counterfactual scenario where the products were cGMP-compliant, Texan would have successfully sold them. They argued this violated the principle that a party must have a fair opportunity to address the essential building blocks of the Tribunal's reasoning.

The Court applied the test from BZW and another v BZV [2022] 1 SLR 1080, which stipulates that a tribunal does not breach natural justice if its reasoning is "open to it" based on the materials and arguments presented. The Court noted at [33]:

"the chain of reasoning that Texan would have been able to sell the products if there was cGMP-compliance (ie, in the counterfactual scenario) was open to the Tribunal and there was no breach of the fair hearing rule"

The Court found that the issue of Texan's ability to sell the products was inherently linked to the claim for storage costs. If the products were compliant, they would have been sold and not stored. Therefore, the Tribunal was entitled to infer that the breach (non-compliance) was the cause of the storage costs. The Court also noted that the Tribunal had relied on the "Break Even Presumption" under English law. As stated at [162]:

"I am fortified in this finding that there exists a presumption under English law that a party claiming damages for the other party’s breach of contract would have broken even on its expenses."

The Court concluded that the Tribunal’s use of this presumption was a matter of legal error (if anything), which is not a ground for setting aside. The natural justice challenge was therefore dismissed.

Analysis of Ground 2: Excess of Jurisdiction

The Court then turned to the more substantial challenge: the imposition of liability on ICI and Dharmesh Mehta. The Court adopted the two-stage enquiry from Bloomberry Resorts and Hotels Inc and another v Global Gaming Philippines LLC and another [2021] 2 SLR 1279:

1. Identify what matters were submitted to the Tribunal for arbitration.
2. Determine whether the Award contains decisions on matters beyond the scope of that submission.

The Court observed that the MRA was a contract solely between IGL and Texan. While the Arbitration Agreement was signed by all four parties, it did not automatically make all four parties liable for every contract mentioned in the dispute. The Court scrutinized Texan’s Statement of Claim and found that Texan had specifically pleaded that "IGL breached the MRA." There was no pleading that ICI or Dharmesh were parties to the MRA or were liable for its breach through some other legal mechanism (like piercing the corporate veil or agency).

The Tribunal, however, had simply lumped all three respondents together in its liability finding. The Court held at [90]:

"In deciding that ICI and Dharmesh were liable for breach of the MRA, the Tribunal thus acted in excess of jurisdiction."

The Court rejected Texan’s argument that the broad language of the Arbitration Agreement ("any and all disputes... in connection with the sale") allowed the Tribunal to find anyone liable for anything. Jurisdiction is limited by the actual issues defined in the pleadings and the course of the arbitration. Since the liability of ICI and Dharmesh for MRA breaches was never a "matter" submitted for determination, the Tribunal had no power to award damages against them on that basis.

What Was the Outcome?

The High Court ordered a partial setting aside of the Final Award. The Court’s order was precise in its excision of the jurisdictional error while preserving the valid portions of the Tribunal’s decision.

The operative order, found at paragraph [100], states:

"I therefore order that the part of the Award concerning the Tribunal’s decision that ICI and Dharmesh are liable to pay Texan damages for breach of the MRA, as well as the Tribunal’s order that ICI and Dharmesh pay such damages in the sum of US$261,275.89 to Texan, be set aside."

The consequences of the judgment are as follows:

• India Glycols Ltd (IGL): Remains fully liable to pay Texan the damages sum of US$261,275.89. No part of the award against IGL was set aside.
• IGL Chem International USA LLC (ICI) and Dharmesh Mehta: Are no longer liable for the damages award. The portion of the award holding them liable was found to be in excess of jurisdiction.
• Costs: The Court did not make an immediate order on costs for the High Court application. Instead, it directed the parties to file written submissions on costs within two weeks (by 7 March 2025) if they could not reach an agreement.
• Set-off: The Court’s decision did not disturb the Tribunal’s calculation of the quantum, which included a deduction of US$127,698.20 (the unpaid invoices) from the US$388,974.09 storage cost claim.

Why Does This Case Matter?

This case is a significant addition to Singapore’s arbitration jurisprudence for several reasons. First, it clarifies the distinction between the scope of an arbitration agreement and the scope of the submission to arbitration. Even where an arbitration agreement is drafted in the broadest possible terms (e.g., "any and all disputes in connection with..."), the Tribunal’s jurisdiction is ultimately circumscribed by the specific issues raised in the pleadings and the evidence. Practitioners cannot rely on a broad arbitration clause to "sweep in" non-parties to a substantive contract unless a specific legal basis for doing so is pleaded and argued.

Second, the judgment reinforces the high threshold for natural justice challenges. By following BZW v BZV, the Court reiterated that tribunals are allowed significant leeway in their "chain of reasoning." As long as the conclusion is a foreseeable outgrowth of the arguments, the Court will not intervene. This provides much-needed certainty for arbitrators, ensuring that they are not constantly looking over their shoulders for fear that a logical inference might be characterized as a "new" argument.

Third, the case highlights the "Break Even Presumption" in English law (which governed the MRA). The Court’s acceptance that a Tribunal can take "judicial notice" of such a presumption—and that doing so is at most an error of law rather than a breach of natural justice—is a vital distinction for practitioners. It underscores that the setting-aside process is not a back-door appeal on the merits.

Finally, the decision demonstrates the utility of the "partial setting aside" mechanism. Rather than striking down the entire award due to a jurisdictional error regarding two of the three respondents, the Court surgically removed only the offending portions. This preserves the efficiency of the arbitration process for the remaining valid claims, aligning with Singapore’s pro-arbitration stance.

Practice Pointers

• Pleading Precision: When dealing with multiple respondents (e.g., parent, subsidiary, and director), claimants must explicitly plead the legal basis for holding each party liable, especially if they are not all signatories to the underlying substantive contract.
• Jurisdictional Audits: At the outset of an arbitration, counsel should conduct a "jurisdictional audit" to ensure that the relief sought against each party is supported by a contract to which that party is a signatory, or a recognized doctrine (like agency or alter ego).
• Counterfactual Ventilation: To avoid natural justice challenges, parties should ensure that counterfactual scenarios (e.g., "what would have happened but for the breach") are explicitly addressed in expert reports and closing submissions.
• The "Matter" Test: Remember that the "matters" submitted to arbitration are determined by the pleadings, the list of issues, and the opening/closing statements. A tribunal cannot decide a "matter" that was not clearly put before it.
• English Law Presumptions: In contracts governed by English law, be aware of the "Break Even Presumption" regarding damages. If you intend to argue that a party would have lost money even without a breach, you must adduce evidence to rebut this presumption.
• Broad Clauses are Not Panaceas: A broad arbitration agreement signed by multiple parties does not override the privity of the underlying substantive contracts. Liability must still be grounded in a cause of action applicable to each specific party.

Subsequent Treatment

As a February 2025 decision, India Glycols Ltd v Texan Minerals and Chemicals LLC is a recent authority. It follows the established doctrinal path set by the Court of Appeal in BZW and another v BZV [2022] 1 SLR 1080 regarding natural justice and Bloomberry Resorts regarding excess of jurisdiction. It is expected to be frequently cited in future Singapore High Court applications involving multi-party arbitration agreements where "lumping" of liability is alleged.

Legislation Referenced

• International Arbitration Act 1994 (2020 Rev Ed), s 24(b)
• UNCITRAL Model Law on International Commercial Arbitration, Art 34(2)(a)(ii)
• UNCITRAL Model Law on International Commercial Arbitration, Art 34(2)(a)(iii)
• Goods Act 1979 (referred to as Sale of Goods Act 1979)

Cases Cited

• Applied: BZW and another v BZV [2022] 1 SLR 1080
• Followed: Inc and another v Global Gaming Philippines LLC and another [2021] 2 SLR 1279 ("Bloomberry Resorts")
• Considered: [2018] SGHC 147
• Referred to:
  • CJA v CIZ [2022] 2 SLR 557
  • Pacific Recreation Pte Ltd v S Y Technology Inc and another appeal [2008] 2 SLR(R) 491
  • TMM Division Maritima SA de CV v Pacific Richfield Marine Pte Ltd [2013] 4 SLR 972
  • BAZ v BBA and others and other matters [2020] 5 SLR 266
  • CBX and another v CBZ and others [2022] 1 SLR 47
  • CDM and another v CDP [2021] 2 SLR 235
  • CAJ and another v CAI and another appeal [2022] 1 SLR 505
  • CKH v CKG and another matter [2022] 2 SLR 1
  • CIM v CIN [2021] 4 SLR 1176
  • Conditioning Equipment Co Ltd v Tornado Consumer Goods Ltd and another matter [2018] 4 SLR 271
  • Swire Shipping Pte Ltd v Ace Exim Pte Ltd [2024] 5 SLR 706

Source Documents

• Original Judgment at eLitigation
• Judgment PDF (CDN)